MATSUO E (JP),МАЦУО Е (JP),KHISADA Sodzi (JP),ХИСАДА Содзи (JP),NAKAMURA Yusuke (JP),НАКАМУРА Юсуке (JP),AKHMED Feryan (US),АХМЕД Ферьян (US),UOKER Dzhoel R. (US),УОКЕР Джоэл Р. (US),KHANTLI Rejmond (,MATSUO E,МАЦУО Е,KHISADA Sodzi,ХИСАДА Содзи,NAKAMURA Yusuke,НАКАМУРА Юсуке,AKHMED Feryan,АХМЕД Ферьян,UOKER Dzhoel R.,УОКЕР Джоэл Р.,KHANTLI Rejmond,ХАНТЛИ Рэймонд
申请号：
RU2014133865
公开号：
RU0002645339C1
申请日:
2012.12.21
申请国别(地区):
RU
年份:
2018
代理人:
摘要：
FIELD: pharmacology.SUBSTANCE: invention relates to a heterocyclic compound of the formula (I) or to a pharmaceutically acceptable salt thereof, wherein X1 is selected from a direct bond or -NH-； Q1 is selected from the group consisting of C5-C7 cycloalkyl, phenyl, pyridyl, pyrazolyl, pyrimidinyl, piperidyl, (C3-C10 cycloalkyl)-C1-C6 alkyl and (3-10-membered non-aromatic heterocyclyl)-C1-C6 alkyl； where Q1 is optionally substituted by one A1； X2 is selected from -CO- and -SO2-； R11 is selected from the group consisting of C1-C6 alkyl and C3-C6 cycloalkyl, which are optionally substituted by one hydroxyl group； R5 is selected from the group consisting of a halogen atom, C6-C10 aryl, 5-10-membered heteroaryl and 3-10-membered non-aromatic heterocyclyl； wherein aryl, heteroaryl and heterocyclyl are optionally substituted by 1 to 3 substituents A3； R2, R3 and R4 represent a hydrogen atom； A1 is selected from the group consisting of C1-C6 alkyl, -NR16R17, -OR18, 3-10-membered non-aromatic heterocyclyl and (CD3)2N-C1-C6 alkyl； where alkyl and heterocyclyl are optionally substituted by one A4 and where heterocyclyl is optionally substituted by one C1-C6 alkyl； A3 is independently selected from the group consisting of a halogen atom, cyano, C1-C6 alkyl and -OR18； R16 is independently selected from the group consisting of a hydrogen atom, C1-C6 alkyl and -COR20； where alkyl is optionally substituted by one A4； R17 is selected from the group consisting of a hydrogen atom and C1-C6 alkyl, which is optionally substituted by one A4； or R18 is selected from the group consisting of a hydrogen atom and C1-C6 alkyl, where alkyl is optionally substituted by one or three A4； R20 is selected from the group consisting of C1-C6 alkyl and 3-10-membered non-aromatic heterocyclyl； wherein alkyl and heterocyclyl are optionally substituted by one amino group； A4 are independently selected from the group consisting of a halogen atom, -NR24R25, hydroxy and 3-10-membered non-aromatic heterocycly
